MET-097i: Innovative Biased GLP-1 Receptor Modulation

adicionou um novo artigo Health

2025-11-09 12:48:02

A new milestone in metabolic medicine, MET-097 i is revolutionizing how obesity and type 2 diabetes are managed. Developed by Metsera, this advanced GLP-1 receptor agonist features a fully biased and ultra-long-acting structure, which extends its therapeutic reach far beyond traditional GLP-1 drugs. Its design allows for far fewer injections—potentially just once per month—greatly...

0 Comentários 0 Compartilhamentos 99 Visualizações 0 Anterior